Organicell Welcomes Dr. George C. Shapiro To The Medical Advisory Board 

Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today announced the appointment of George C. Shapiro, M.D. F.A.C.C. to its medical advisory board. In addition to serving on the Company’s Advisory Board, Dr. Shapiro is assembling the medical advisory board for Organicell.

Dr. Shapiro is a world-renowned cardiologist, a leading speaker on age-management medicine, the holder of two US patents, and had a fellowship in cardiovascular disease at Columbia Presbyterian Medical Center in New York.
In addition to building a medical advisory board, Dr. Shapiro will play an instrumental role in the clinical trials for Organicell’s new biologic medicines.

“We are honored that Dr. Shapiro agreed to join our Board of Directors,” said Organicell CEO Manny Iglesias. “He will be assembling a world-class medical advisory board to help guide the Company along the cutting-edge of medical science as we develop and test Exosome-based therapies.”

Dr. Shapiro stated, “I look forward to working with CEO Manny Iglesias and his team as they develop new biologic medicines and stem-cell based exosome therapies.”

About Organicell

Organicell is the leading, fully integrated Exosome Therapeutics Company. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicine. We believe that our ground-breaking research in the field of nanotechnology, specifically exosomes and other micro vesicles, is the next frontier of stem cell-based exosome therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients.

Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.

Forward Looking Statements

This Press Release may contain information considered to be forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflects management’s expectations. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to financial situation, competition, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, inability to expand sales and channels, legislation or regulations affecting product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements.

Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press releases.

CONTACT: Ian Bothwell, 310-200-9741